Key Highlights

  • Iovance Biotherapeutics shares closed at $10.80 today, up 5.99%.
  • The move extends a multi-week surge driven by growing analyst optimism around its Amtagvi franchise, following recent price target hikes.
  • Second-quarter Amtagvi Revenue reached nearly $100 million, up 66% year-over-year, with record gross margins.
  • Shares are now trading near 52-week highs and up more than 240% year-to-date despite broader market weakness tied to surging Treasury yields.

Analyst Optimism Around Amtagvi Continues to Build

Iovance Biotherapeutics (NASDAQ:IOVA) shares closed higher today, extending a multi-week surge driven by growing analyst optimism around its Amtagvi (lifileucel) franchise. The move follows recent price target hikes and bullish commentary from analysts citing a clear line of sight to profitability, alongside anticipation of an upcoming lung cancer trial update.

Record Revenue Reinforces the Bullish Case

Management's commentary from mid-September highlighted record second-quarter Amtagvi revenue of nearly $100 million, up 66% year-over-year, with record gross margins reported for the quarter. That combination of accelerating revenue growth and improving margins has helped drive the stock to trade near 52-week highs and up more than 240% year-to-date, even as the broader market has faced weakness tied to surging Treasury yields.

A Pioneer in Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics is a San Carlos, California-based commercial-stage biopharmaceutical company pioneering tumor infiltrating lymphocyte cell therapies to treat solid tumor cancers by harnessing patients' own immune systems. Its flagship product, Amtagvi (lifileucel), is the first FDA-approved TIL therapy for advanced melanoma, complemented by Proleukin, an IL-2 product used in the treatment regimen, and the company maintains a pipeline of next-generation TIL and IL-2 therapies targeting additional indications, including cervical, head and neck squamous cell carcinoma and non-small cell lung cancer.